Advertisement

Topics

Axovant licenses worldwide rights to Benitec's BB301 and five other CNS gene therapy programs

15:40 EDT 12 Jul 2018 | Elsevier Business Intelligence

Axovant Sciences Ltd. licensed exclusive worldwide rights to Benitec Biopharma Ltd.'s preclinical oculopharyngeal muscular dy...

Original Article: Axovant licenses worldwide rights to Benitec's BB301 and five other CNS gene therapy programs

NEXT ARTICLE

More From BioPortfolio on "Axovant licenses worldwide rights to Benitec's BB301 and five other CNS gene therapy programs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...